John McKearn

John P.
McKearn currently works at Arch Oncology, Inc., as Chairman from 2016, RiverVest Venture Management LLC, as Managing Director from 2008, OxaluRx, Inc., as Director, OncoResponse, Inc., as Director, Good Therapeutics, Inc., as Director, Bonum Therapeutics, Inc., as Director, and Wugen, Inc., as Director from 2022.
Dr. McKearn also formerly worked at Kalypsys, Inc., as President & Chief Executive Officer from 2003 to 2008, Epimmune, Inc., as Director, Adarza BioSystems, Inc., as Director, Lumena Pharmaceuticals, Inc., as Director from 2011 to 2014, IDM Pharma, Inc., as Director from 2000 to 2009, Allakos, Inc., as Independent Director from 2012 to 2023, Otonomy, Inc., as Independent Director from 2010 to 2015, ZS Pharma, Inc., as Director, Keel Pharmaceuticals, Inc., as Director, EIDP, Inc., as Senior Scientist from 1985 to 1987, Pharmacia Corp., as Head-Discovery Research from 1997 to 2003, Washington University in St. Louis, as Research Associate, BioGenerator (Venture Capital), as Investment Committee, Searle & Co., Inc., as Head-Discovery Research in 2003, G.D.
Searle LLC, as Head-Discovery Research from 1997 to 2003, and Basel Institute for Immunology, as Member from 1982 to 1985.
Dr. McKearn received his undergraduate degree in 1975 from Northern Illinois University and doctorate degree in 1979 from The University of Chicago.